ETC
PTGX icon

Exchange Traded Concepts’s Protagonist Therapeutics PTGX Stock Holding History

Exchange Traded Concepts’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.51M Sell
23,773
-11,266
-32% -$998K 0.02% 546
2025
Q4 		$3.06M Buy
35,039
+1,487
+4% +$122K 0.02% 500
2025
Q3 		$2.23M Sell
33,552
-13,839
-29% -$787K 0.02% 541
2025
Q2 		$2.62M Buy
47,391
+19,999
+73% +$960K 0.03% 432
2025
Q1 		$1.32M Buy
27,392
+26,367
+2,572% +$1.1M 0.02% 471
2024
Q4 		$39.6K Buy
1,025
+64
+7% +$2.79K ﹤0.01% 1239
2024
Q3 		$43.2K Buy
+961
New +$38.8K ﹤0.01% 1209

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Exchange Traded Concepts's PTGX Position: Q1 2026 in Review

Exchange Traded Concepts reduced its Protagonist Therapeutics (PTGX) stake by 32% in Q1 2026, selling an estimated $998K and leaving 23,773 shares worth $2.51M. The position accounts for 0.02% of the portfolio, ranked #546.

Exchange Traded Concepts first reported a position in PTGX in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.06M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Exchange Traded Concepts held 23,773 shares of Protagonist Therapeutics worth $2.51M as of Q1 2026.
  • Exchange Traded Concepts sold 11,266 Protagonist Therapeutics shares in Q1 2026, an estimated $998K.
  • Protagonist Therapeutics made up 0.02% of Exchange Traded Concepts's portfolio in Q1 2026, its #546 holding.
  • Exchange Traded Concepts first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Exchange Traded Concepts's Protagonist Therapeutics position peaked at $3.06M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Exchange Traded Concepts's 13F filing for Q1 2026, filed 15 Apr 2026.